Jon Cuthbert

Binance and its founder Changpeng Zhao are facing a £150 million (US$200 million) lawsuit from almost 1,700 UK investors.

The total number of Australian building approvals fell 1.1% in May to 17,019 dwellings, driven by a decline in apartment approvals.

The Singapore International Commercial Court (SICC) awarded more than US$3 million to 40 investors after finding Terraform Labs and Do Kwon liable for fraudulent representations about TerraUSD (CRYPTO:UST) during its May 2022 collapse.

Open Standard announced that BlackRock, Coinbase, Ripple and Mastercard have joined the Open USD stablecoin project.

Biome Australia (ASX:BIO) has reported a 30% increase in preliminary annual sales revenue to $23.9 million for FY26.

The US Securities and Exchange Commission (SEC) has opened a 60-day public consultation on whether existing rules adequately regulate exchange-traded funds using new asset classes and investment strategies.

Abivax stock climbed more than 30% after the French biotech released additional data from its late-stage trial of obefazimod, showing that cancer cases in the study were consistent with background rates expected in that patient population.

Stoke Therapeutics Inc. (NASDAQ:STOK) said it has completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen, an investigational RNA medicine for Dravet syndrome.

Unicycive Therapeutics (NASDAQ:UNCY) said the U.S. Food and Drug Administration issued a Complete Response Letter for its resubmitted new drug application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis.

Novocure (NASDAQ:NVCR) said its Optune Pax device has received CE Mark approval for treating adult patients with locally advanced pancreatic cancer of exocrine origin in combination with gemcitabine and nab-paclitaxel.